Search results
Results from the WOW.Com Content Network
Levetiracetam, sold under the brand name Keppra among others, is a novel antiepileptic drug [7] used to treat epilepsy. [8] It is used for partial-onset , myoclonic , or tonic–clonic seizures, [ 7 ] and is taken either by mouth as an immediate or extended release formulation or by injection into a vein .
COVID-19 drug development is the research process to ... As of March 2022 has over 16,000 people enrolled as participants making it the largest study into COVID-19 ...
Researchers at Boston’s Dana-Farber Cancer Institute are working on a drug that takes one of the virus’s most dangerous traits — its talent for mutation — and turns it back on itself.
[5] [93] [94] [95] One study from April 2020 found that people with COVID-19 and hypertension had lower all-cause mortality when on these medications. [96] Similar concerns were raised about non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen; these were likewise not borne out, and NSAIDs may both be used to relieve symptoms of ...
For premium support please call: 800-290-4726 more ways to reach us
Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November ...
In March 2020, then US President Donald Trump promoted the use of chloroquine and hydroxychloroquine, two related anti-malarial drugs, for treating COVID-19. The FDA later clarified that it has not approved any therapeutics or drugs to treat COVID-19, but that studies were underway to see if chloroquine could be effective in treatment of COVID-19.
Seletracetam (UCB 44212) is a pyrrolidone-derived [2] drug of the racetam family that is structurally related to levetiracetam (trade name Keppra). [2] [3] It was under development by UCB Pharmaceuticals as a more potent and effective anticonvulsant drug to replace levetiracetam but its development has been halted.